Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus

Gong,Han-Xian; He,Lei; Li,Xiang-Pen; Wang,Yi-Dong; Li,Yi; Huang,Jun-Jian; Wang,Ziling; Xie,Dan; Kung,Hsiang-Fu; Peng,Ying

doi:10.3892/or.2011.1619

Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus

Authors:
- Han-Xian Gong
- Lei He
- Xiang-Pen Li
- Yi-Dong Wang
- Yi Li
- Jun-Jian Huang
- Ziling Wang
- Dan Xie
- Hsiang-Fu Kung
- Ying Peng
View Affiliations

Affiliations: Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China, Laboratory of Tumor and Molecular Biology, Beijing Institute of Biotechnology, Beijing, P.R. China, Institute of Blood Transfusion; Academy of Military Medical Sciences, Beijing, P.R. China, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China, Stanley Ho Center for Emerging Infectious Diseases, the Chinese University of Hong Kong, Shatin, Hong Kong SAR, P.R. China
Published online on: December 30, 2011 https://doi.org/10.3892/or.2011.1619
Pages: 1163-1169

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

hTERTC27, a 27-kDa hTERT C-terminal polypeptide has been demonstrated to cause hTERT-positive HeLa cell apoptosis and inhibits the growth of mouse melanoma. hTERTC27 has been associated with telomere dysfunction, regulation of gene-regulated apoptosis, the cell cycle and activation of natural killer (NK) cells, but its mechanism of action is not fully understood. Here, we report that dendritic cells (DCs) transduced with hTERTC27 can increase T-cell proliferation, and augment the concentration of interleukin-2 (IL-2) and interferon-γ (IFN-γ) in the supernatants of T cells. It can also induce antigen-specific cytotoxic T lymphocytes (CTL) against glioma cells in vitro. Moreover, hTERTC27 gene-transduced DCs exhibit a very potent cytotoxicity to glioma cells in vivo. It could prolong the survival time and inhibit the growth of glioma-bearing mice. These data suggest that hTERTC27 gene-transduced DCs can efficiently enhance immunity against gliomas in vitro and in vivo.

View Figures

View References

1	Tanaka H, Shinto O, Yashiro M, et al: Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep. 24:1637–1643. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kushwah R and Hu J: Complexity of dendritic cell subsets and their function in the host immune system. Immunology. 133:409–419. 2011. View Article : Google Scholar : PubMed/NCBI
3	Phuc PV, Lam DH, Ngoc VB, Thu DT, Nguyet NT and Ngoc PK: Production of functional dendritic cells from menstrual blood-a new dendritic cell source for immune therapy. In Vitro Cell Dev Biol Anim. 47:368–375. 2011.PubMed/NCBI
4	Guermonprez P, Valladeau J, Zitvogel L, Thery C and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 20:621–667. 2002. View Article : Google Scholar : PubMed/NCBI
5	Pawlowska AB, Hashino S, McKenna H, Weigel BJ, Taylor PA and Blazar BR: In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in non-transplanted or syngeneic bone marrow-transplanted mice. Blood. 97:1474–1482. 2001. View Article : Google Scholar
6	Onaitis M, Kalady MF, Pruitt S and Tyler DS: Dendritic cell gene therapy. Surg Oncol Clin N Am. 11:645–660. 2002. View Article : Google Scholar : PubMed/NCBI
7	Trivedi D, Williams RY, O'Reilly RJ and Koehne G: Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 105:2793–2801. 2005. View Article : Google Scholar
8	Bachleitner-Hofmann T, Friedl J, Hassler M, et al: Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep. 21:1585–1592. 2009. View Article : Google Scholar
9	Xiao ZY, Tang H, Xu ZM, et al: An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol Ther. 11:974–980. 2011. View Article : Google Scholar : PubMed/NCBI
10	Palucka AK, Ueno H, Connolly J, et al: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. J Immunother. 29:545–557. 2006. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Liu J, Cao X, et al: Enhancement of antigen presenting function of dendritic cells by IL-2 gene modification and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 23:247–250. 2002.(In Chinese).
12	Harrington L, Zhou W, McPhail T, et al: Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11:3109–3115. 1997. View Article : Google Scholar : PubMed/NCBI
13	Collins K and Mitchell JR: Telomerase in the human organism. Oncogene. 21:564–579. 2002. View Article : Google Scholar : PubMed/NCBI
14	Shay JW, Zou Y, Hiyama E and Wright WE: Telomerase and cancer. Hum Mol Genet. 10:677–685. 2001. View Article : Google Scholar
15	Zhang P, Chen Y, Jiang X, Tu Z and Zou L: Tumor-targeted efficiency of shRNA vector harboring chimera hTERT/U6 promoter. Oncol Rep. 23:1309–1316. 2010.PubMed/NCBI
16	Li H, Wang J, Zhou T, Zhang Y and Zhang Z: An investigation of the effects of nanosize delivery system for antisense oligonucleotide on esophageal squamous cancer cells. Cancer Biol Ther. 7:1852–1859. 2008. View Article : Google Scholar : PubMed/NCBI
17	Keith WN, Bilsland A, Evans TR and Glasspool RM: Telomerase-directed molecular therapeutics. Expert Rev Mol Med. 4:1–25. 2002. View Article : Google Scholar : PubMed/NCBI
18	Vonderheide RH, Hahn WC, Schultze JL and Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 10:673–679. 1999. View Article : Google Scholar : PubMed/NCBI
19	Huang JJ, Lin MC, Bai YX, et al: Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res. 62:3226–3232. 2002.
20	Ng SS, Gao Y, Chau DH, et al: A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther. 14:561–572. 2007. View Article : Google Scholar : PubMed/NCBI
21	Huo L, Yao H, Wang X, Wong GW, Kung HF and Lin MC: Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice. PLoS One. 5:e127052010. View Article : Google Scholar : PubMed/NCBI
22	Yang JY, Cao DY, Liu WC, Zhang HM, Teng ZH and Ren J: Dendritic cell generated from CD34⁺ hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cell Immunol. 240:14–21. 2006.PubMed/NCBI
23	Chen T, Tang XD, Wan Y, et al: HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia. 10:977–986. 2008.PubMed/NCBI
24	Inaba K, Inaba M, Romani N, et al: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 176:1693–1702. 1992. View Article : Google Scholar
25	Berzofsky JA, Terabe M, Oh S, et al: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 113:1515–1525. 2004. View Article : Google Scholar : PubMed/NCBI
26	Vonderheide RH, Domchek SM, Schultze JL, et al: Vaccination of cancer patients against telomerase induces functional antitumor CD8⁺ T lymphocytes. Clin Cancer Res. 10:828–839. 2004. View Article : Google Scholar : PubMed/NCBI
27	Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
28	Huo LF, Tang JW, Huang JJ, et al: Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol. 3:1–11. 2006.PubMed/NCBI
29	Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL and Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 7:3343–3348. 2001.PubMed/NCBI
30	Scardino A, Gross DA, Alves P, et al: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 168:5900–5906. 2002. View Article : Google Scholar : PubMed/NCBI
31	Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA. 97:4796–4801. 2000. View Article : Google Scholar : PubMed/NCBI
32	Rabinovich PM, Komarovskaya ME, Wrzesinski SH, et al: Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther. 20:51–61. 2009. View Article : Google Scholar : PubMed/NCBI
33	Iuchi T, Teitz-Tennenbaum S, Huang J, et al: Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res. 68:4431–4441. 2008. View Article : Google Scholar : PubMed/NCBI
34	Dredge K, Marriott JB, Todryk SM, et al: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 168:4914–4919. 2002. View Article : Google Scholar : PubMed/NCBI
35	Pletneva M, Fan H, Park JJ, et al: IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res. 69:6607–6614. 2009. View Article : Google Scholar : PubMed/NCBI